Daily Hong Kong Stock Market News Express (Friday, September 20)

< br > < b > Stock News < br > < span class = "section-news" > 1. Zhengrong Real Estate (06158.HK): The deadline for the restructuring support agreement has been further extended. < br > < span class = "section-news" > 2. China Stock Exchange (03969.HK): From July to August, a total of six important projects in the rail transit market won the bidding amount of about 2.90 billion yuan, accounting for about 7.84% of the audited operating income in 2023. < br > < span class = "section-news" > 3. Jinyang New Energy (01121.HK): Affiliated has entered into a joint venture agreement with Juneng and Longji to establish a joint venture company to produce HBC solar cells. < br > < span class = "section-news" > 4. Okonvision Bio B (01477.HK): OT-1001 new drug registration application approved by the State Drug Administration. < br > < class span = "section-news" > 5. China Biotechnology Service (08037.HK) plans to cooperate with Jinshazhou Hospital of Guangzhou University of Traditional Chinese Medicine in the fields of boron neutron capture therapy drugs and medical apparatus, referral cooperation, equity cooperation, and indication expansion. < br > < span class = "section-news" > 6. Fussen Pharmaceutical (01652.HK): The application for the clinical trial of Class 1.1 traditional Chinese medicine innovative drug "SY617" was approved. < br > < span class = "section-news" > 7. Xinhua Wenxuan (00811.HK): Signed a 1.256 billion yuan procurement contract to become a single source supplier of textbooks for students in compulsory education in Sichuan Province. < br > < span class = "section-news" > 8. Sunshine Insurance (06963.HK): Sunshine Life Insurance premium income 66.384 billion yuan from January to August.